Our expert reasonably tells us
the fragmented market for latent tuberculosis testing, particularly in the USA and Europe, poses a significant challenge to Cellestis in continuing growth in QuantiFERON-TB Gold In-Tube sales.
OK, that makes sense. But then our expert also reasonably tells us
Cellestis has achieved strong revenue and earnings growth in the past few years and is expected to continue to do so in the near term as QuantiFERON-TB Gold In-Tube continues to develop its market share
If sales continue as expected you would think that the "fragmentation" would diminish accordingly, que?
